Sulfatinib (b)( HMPL-012 | Surufatinib | HMPL012 )

Catalog No. M11232 CAS No. 1308672-74-3

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Group Booking Get Quotation Bulk Inquiry Add to Cart

Product Name

Sulfatinib (b)
Note

Research use only, not for human use.
Brief Description

Sulfatinib (HMPL-012) is a potent, multi-targeted tyrosine kinase inhibitor of VEGFR-1/2/3, FGFR1, CSF1R with IC50 of 2/24/1 nM, 15 nM, 4 nM, respectively.
Description

Sulfatinib (HMPL-012) is a potent, multi-targeted tyrosine kinase inhibitor of VEGFR-1/2/3, FGFR1, CSF1R with IC50 of 2/24/1 nM, 15 nM, 4 nM, respectively; also potently inhibits TrkB and FLT-3 with IC50 of 41 and 67 nM, shows little to no activity against other 278 other kinases (IC50>150 nM); targets tumor angiogenesis and immune modulation, exhibits an acceptable safety profile and encouraging antitumor activity in clinical investigations.Brain Cancer Phase 3 Clinical.
In Vitro

——
In Vivo

——
Synonyms

HMPL-012 | Surufatinib | HMPL012
Pathway

Cancer
Target

Brain Cancer
Recptor

VEGFR
Research Area

Cancer
Indication

Brain Cancer

CAS Number

1308672-74-3
Formula Weight

480.5825
Molecular Formula

C24H28N6O3S
Purity

>98% (HPLC)
Solubility

DMSO: ≥ 30 mg/mL
SMILES

CC1=CC2=C(N1)C=CC(OC3=NC(NC4=CC(CS(NCCN(C)C)(=O)=O)=CC=C4)=NC=C3)=C2
Chemical Name

Benzenemethanesulfonamide, N-[2-(dimethylamino)ethyl]-3-[[4-[(2-methyl-1H-indol-5-yl)oxy]-2-pyrimidinyl]amino]-

1. Xu JM, et al. Oncotarget. 2017 Jun 27;8(26):42076-42086.

Calculator

molnova catalog